Ms. Eastland is a seasoned strategic and financial executive with more than 25 years of experience in corporate finance, corporate development, financial planning and analysis, investor relations and operations.
She previously served as chief financial officer and chief business officer of Rainier Therapeutics, a private biopharmaceutical company focused on developing treatments for bladder cancer. Prior to Rainier, Eastland served as chief financial officer and chief business officer of Cascadian Therapeutics, a publicly traded oncology company that was acquired by Seattle Genetics in 2018. While at Cascadian, Eastland was instrumental in the negotiation and sale of the company, primarily for its product tucatinib, a HER2 targeted breast cancer therapy now marketed as Tukysa:registered:. Before Cascadian, she served as chief financial officer and vice president of operations at VLST Corporation, a private biotechnology company, and also held financial and strategic management positions of increasing responsibility at Dendreon and Amgen.
Eastland received an M.B.A. from Edinburgh University Management School and a B.S. in finance from Colorado State University. Eastland serves on the board of directors for Dynavax Technologies (Nasdaq: DVAX), Graybug Vision (Nasdaq: GRAY) and Harpoon Therapeutics (Nasdaq: HARP).